Infect Control Hosp Epidemiol by Han, Jennifer H. et al.
Risk Factors for Gastrointestinal Tract Colonization with
Extended-Spectrum β-Lactamase (ESBL)–Producing Escherichia
coli and Klebsiella Species in Hospitalized Patients
Jennifer H. Han, MD, MSCE1, Irving Nachamkin, DrPH, MPH2, Theoklis E. Zaoutis, MD,
MSCE3,4, Susan E. Coffin, MD, MPH3,4, Darren R. Linkin, MD, MSCE1,3,5, Neil O. Fishman,
MD1, Mark G. Weiner, MD6, Baofeng Hu, MD2, Pam Tolomeo, MPH3,7, and Ebbing
Lautenbach, MD, MPH, MSCE1,3,7
1Division of Infectious Diseases, Department of Medicine, University of Pennsylvania School of
Medicine, Philadelphia, Pennsylvania
2Department of Pathology and Laboratory Medicine, University of Pennsylvania School of
Medicine, Philadelphia, Pennsylvania
3Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of
Medicine, Philadelphia, Pennsylvania
4Division of Infectious Diseases, and Center for Pediatric Clinical Effectiveness, Children’s
Hospital of Philadelphia, Philadelphia, Pennsylvania
5Philadelphia Veterans Affairs Medical Center, Philadelphia, Pennsylvania
6Division of General Internal Medicine, Department of Medicine, University of Pennsylvania
School of Medicine, Philadelphia, Pennsylvania
7Department of Biostatistics and Epidemiology, University of Pennsylvania School of Medicine,
Philadelphia, Pennsylvania
Abstract
We describe the prevalence of and risk factors for colonization with extended-spectrum β-
lactamase (ESBL)–producing Escherichia coli and Klebsiella species (ESBL-EK) in hospitalized
patients. The prevalence of colonization with ESBL-EK was 2.6%. Colonization was associated
with cirrhosis, longer duration of hospital stay prior to surveillance, and prior exposure to
clindamycin or meropenem.
Infections owing to extended-spectrum β-lactamase (ESBL)–producing Enterobacteriaceae,
most commonly Escherichia coli and Klebsiella species (EK), are associated with increased
morbidity and mortality.1 Asymptomatically colonized patients may contribute to the
reservoir in the hospital setting and increase the risk of patient-to-patient transmission.
While several studies have evaluated risk factors for colonization with ESBL-producing
Enterobacteriaceae,2–6 these have been limited to specific patient populations (eg, intensive
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care unit [ICU] patients). Therefore, we conducted this study to determine the prevalence of,
and risk factors for, colonization with ESBL-EK in a hospital-wide patient population.
METHODS
This case-control study was conducted at the Hospital of the University of Pennsylvania, a
725-bed academic tertiary care medical center. A total of 4 hospital-wide fecal surveillance
surveys were performed every 4–8 months from April 23, 2007, to March 17, 2009. All
patient care units were included (ie, all hospital floors or ICUs). All subjects were
considered eligible and were approached for informed consent, with each patient included
only once per survey. Once consent was obtained, a perirectal swab was collected for
processing.
Identification of E. coli and Klebsiella species and antimicrobial susceptibility testing were
performed and interpreted in accordance with Clinical and Laboratory Standards Institute
(CLSI) criteria using the semiautomated Vitek 2 identification and susceptibility system
(bioMérieux).7 Confirmatory testing for ESBL production was performed using the double-
disk confirmation method.7 Isolates were tested for the presence of ESBLs (ie, K.
pneumoniae carbapenemase [KPC], TEM, SHV, and CTX-M enzymes) using real-time
polymerase chain reaction.8 Cases and controls were defined solely on the isolation of
ESBL-EK from the surveillance culture, with case patients designated as those who were
ESBL-EK-positive, and control patients as those who were ESBL-EK-negative.
Data were abstracted from the Pennsylvania Integrated Clinical and Administrative
Research Database, which includes demographic, laboratory, and pharmacy information.
Information was collected on baseline demographics, origin at the time of admission,
hospital location, and length of stay prior to sampling. Comorbid conditions were
documented, including diabetes mellitus, cirrhosis, renal insufficiency, malignancy,
infection with human immunodeficiency virus, neutropenia, and transplant. Data were
collected on all antimicrobial and immunosuppressive agents administered during the 30
days prior to sampling. Chart review was performed to ascertain the presence of any positive
clinical cultures for ESBL-EK following the surveillance culture date to discharge or death.
Cases and controls were characterized by potential risk factors, including demographics,
comorbidities, and prior antimicrobial use. Continuous variables were compared using the
Wilcoxon rank-sum test, and categorical variables were compared using Fisher exact test.
Bivariable analyses were performed to determine the association between potential risk
factors and ESBL-EK colonization. An odds ratio (OR) and 95% confidence interval (CI)
were calculated to evaluate the strength of any association. Given the small number of cases,
multivariable analyses were not performed. For all calculations, a 2-tailed P value of less
than .05 was considered significant. All statistical calculations were performed using
STATA software ver. 11.0 (StataCorp). This study was reviewed and approved by the
institutional review board of the University of Pennsylvania.
RESULTS
Over the 2-year study period, study personnel approached a total of 992 patients, of which
437 provided informed consent. Of these, 389 patients subsequently had perirectal swabs
obtained. The median age of patients was 59 years (interquartile range [IQR], 48–68 years)
and 171 (44.0%) were female. Furthermore, 232 (59.6%) were white, 108 (27.8%) were
black, 11 (2.8%) were Hispanic, and 38 (9.8%) were self-identified as “other.”
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Among the 389 patients, 10 (2.6%) were colonized with ESBL-EK. Of these, 4 isolates were
E. coli, and 6 were K. pneumoniae. Two of the K. pneumoniae isolates were KPC-positive.
All 4 of the E. coli isolates were CTX-M-positive. The proportion of ESBL-EK isolates did
not vary significantly across study year (3.2% in 2007, 2.6% in 2008, and 1.7% in 2009; P
= .86).
Results of bivariable analyses are shown in Table 1. Case patients had a significantly longer
duration of hospitalization prior to sampling compared to control patients (mean, 28.9 days
vs 7.8 days, respectively; P < .001). The presence of cirrhosis (P = .006) and prior receipt of
either meropenem (P = .01) or clindamycin (P = .04) were significantly associated with
ESBL-EK colonization.
Of the 10 patients with ESBL-EK colonization, there were 3 groups of case patients with
overlapping dates of hospitalization. However, patients within each group were not located
on the same unit. Four (40%) patients with ESBL-EK colonization had subsequent clinical
cultures that tested positive for ESBL-EK, compared to 1 (0.3%) control patient (P < .001).
Notably, these patients had positive clinical cultures a mean of 8.8 days after the
surveillance culture date. None of the patients had positive ESBL-EK clinical cultures prior
to the sampling date.
DISCUSSION
In this 2-year hospital-wide study, we found that the prevalence of gastrointestinal
colonization with ESBL-EK was 2.6%. Previous studies evaluating colonization with ESBL-
producing Enterobacteriaceae in hospitalized patients2–6 have demonstrated a wide range of
prevalence rates from ~1% to 38% in an outbreak setting. The prevalence of ESBL-EK
colonization in the present study was comparable to those reported from studies performed
in academic tertiary care centers in the United States,5,6 although these were focused on ICU
and high-risk populations.
We found that ESBL-EK colonization was associated with the recent use of clindamycin or
meropenem. Antimicrobial use induces emergence of resistant organisms through pressure
on endogenous flora, and it is likely that various antimicrobials identified as risk factors
across studies4,6 are institution-dependent. Therefore, interventions to decrease ESBL spread
in the hospital setting should focus on appropriate use of antimicrobials overall rather than
restriction of specific classes. Alternatively, infection control interventions (eg, barrier
precautions) may be more important for control of ESBL-EK in the hospital setting, and
further research is needed on evaluating strategies to this effect.
Furthermore, 40% of patients in our study that were colonized with ESBL-EK had a
subsequent positive clinical culture for ESBL-EK during hospitalization. Given that receipt
of inappropriate antimicrobial therapy is associated with increased mortality in patients with
infections due to ESBL-producing organisms,9 knowledge of ESBL-EK colonization status
may help guide empiric antimicrobial therapy for nosocomial infections (eg, carbapenems).
Notably, 60% of patients in our study who were colonized with ESBL-EK did not have
positive clinical cultures and were never placed on barrier precautions. Asymptomatically
colonized patients may act as a reservoir for persistence of ESBL-EK in the hospital setting,
and this may provide further rationale for routine surveillance screening in high-risk
populations.
Our study demonstrated an increased risk for colonization with ESBL-EK in patients with
cirrhosis. This association is of particular concern given studies reporting an increased risk
of infection with ESBL-EK in this patient population.10 Further work is needed to elucidate
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mechanisms leading to ESBL-EK colonization and subsequent infection in patients with
cirrhosis.
Potential limitations of our study include selection bias as only ~44% of eligible subjects
were enrolled. Misclassification bias is a concern in case-control studies. However, testing
for ESBL-production was performed prior to data collection, and cases and controls were
drawn from the same population and classified solely based on ESBL positivity. Finally, the
present study was conducted in an academic medical system, and these results may not be
generalizable to other settings.
In conclusion, our study demonstrates a hospital-wide prevalence rate of 2.6% for ESBL-EK
colonization. Future studies should focus on elucidating optimal infection prevention
interventions to limit spread of ESBL-producing organisms in the hospital setting, including
the role of routine surveillance screening in specific target populations.
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TABLE 1
Bivariable Analyses of Risk Factors for Colonization with ESBL-Producing E. coli or Klebsiella Species in
Hospitalized Patients
Variable Cases (n = 10) Controls (n = 379) OR (95% CI) P value
Age, mean years (SD) 61.0 (10.4) 57.5 (15.4) … .45
Female sex 8 (80.0) 163 (43.0) 5.30 (1.03–51.7) .03
Nonwhite race 3 (30.0) 154 (40.6) 0.63 (0.10–2.80) .75
Duration of hospitalization prior to culture date, mean days (SD) 28.9 (38.9) 7.8 (10.5) … .001
Admitted as a transfer 1 (10.0) 75 (19.8) 0.45 (0.01–3.43) .69
Admitted through the ED 7 (70.0) 184 (48.6) 2.47 (0.55–15.0) .21
Prior hospitalization in UPHS ≤30 days before culture date 4 (40.0) 51 (13.5) 4.29 (0.85–18.7) .05
Year of sampling
 2007 5 (50.0) 151 (39.8)
 2008 3 (30.0) 113 (29.8) … .86
 2009 2 (20.0) 115 (30.4)
Congestive heart failure 3 (30.0) 82 (21.6) 1.55 (0.25–6.98) .46
Diabetes mellitus 1 (10.0) 125 (33.0) 0.23 (0.01–1.67) .18
HIV 0 (0.0) 8 (2.1) … >.99
Malignancy 4 (40.0) 129 (34.0) 1.29 (0.26–5.56) .74
Cirrhosis 3 (30.0) 13 (3.4) 12.1 (1.78–59.9) .006
Transplant 1 (10.0) 55 (14.5) 0.65 (0.01–4.89) >.99
Renal insufficiencya 4 (40.0) 75 (19.8) 2.70 (0.55–11.7) .12
Neutropenia 1 (10.0) 42 (11.1) 0.89 (0.02–6.72) >.99
Mean Charlson score (SD) 3.7 (3.1) 3.5 (3.5) … .64
Receipt of any immunosuppression ≤30 days prior to culture date 4 (40.0) 129 (34.0) 1.29 (0.26–5.56) .74
Receipt of corticosteroids ≤30 days prior to culture date 4 (40.0) 124 (32.7) 1.37 (0.28–5.90) .74
ICU location on culture date 3 (30.0) 48 (12.7) 2.96 (0.48–13.4) .13
Receipt of antimicrobial therapy ≤30 days prior to culture dateb
 Amikacin 1 (10.0) 7 (1.9) 5.90 (0.12–54.5) .19
 Clindamycin 2 (20.0) 11 (2.9) 8.36 (0.77–48.9) .04
 Gentamicin 2 (20.0) 22 (5.8) 4.06 (0.39–22.0) .12
 Meropenem 3 (30.0) 16 (4.2) 9.72 (1.47–47.2) .01
 Aminoglycoside 3 (30.0) 33 (8.7) 4.49 (0.71–20.7) .06
NOTE. Data are presented as no. (%), unless otherwise indicated. CI, confidence interval; ED, emergency department; ESBL, extended-spectrum
β-lactamase; HIV, human immunodeficiency virus; ICU, intensive care unit; OR, odds ratio; SD, standard deviation; UPHS, University of
Pennsylvania Health System.
aCreatinine ≥ 2.0 mg/dL or requirement for dialysis.
bOnly antimicrobial agents with P < .20 are shown.
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